NCT05996094 is a clinical trial in HIV Infections, sponsored by Zamrotul Izzah.

Who is sponsoring NCT05996094?

NCT05996094 is sponsored by Zamrotul Izzah.

What condition does NCT05996094 study?

NCT05996094 studies HIV Infections, AIDS, Antiretroviral Therapy, Highly Active, Adherence, Medication, Drug-level Monitoring.

Is NCT05996094 still recruiting?

NCT05996094 is currently status unknown. Last updated 21 August 2023.

Last reviewed 2023-08-21 · How we verify

NCT05996094

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antiretroviral Adherence and Drug-level Monitoring

Status unknown Last updated 21 August 2023

What this trial tests

trial in HIV Infections in 100 participants. Status unknown.

Timeline

16 October 2020

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Zamrotul Izzah
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	16 October 2020
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Indonesia

Conditions studied

HIV Infections — all drugs for HIV Infections →
AIDS — all drugs for AIDS →
Antiretroviral Therapy, Highly Active — all drugs for Antiretroviral Therapy, Highly Active →
Adherence, Medication — all drugs for Adherence, Medication →

Sponsor

Zamrotul Izzah

Who can join

18 and older, any sex, with HIV Infections or AIDS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational study aims to investigate medication adherence and drug-level monitoring of antiretroviral agents in a cohort of people living with HIV in Indonesia. The study is conducted in outpatients receiving tenofovir-based regimens in a university medical centre.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05996094 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zamrotul Izzah
Last refreshed: 21 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05996094.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing